GeneDx Holdings (WGS) Change in Receivables (2020 - 2026)

GeneDx Holdings (WGS) has reported Change in Receivables for 7 consecutive years, with $6.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables rose 401.65% year-over-year to $6.7 million in Q2 2026; TTM through Jun 2026 was $35.6 million, a 64.04% increase from a year earlier, with the FY2025 full-year figure at $36.2 million, up 599.44% from the prior year.
• Change in Receivables was $6.7 million for Q2 2026 at GeneDx Holdings, up from $2.6 million in the prior quarter.
• Over five years, Change in Receivables peaked at $13.4 million in Q4 2025 and troughed at -$13.5 million in Q2 2022.
• A 5-year average of $1.9 million and a median of $82000.0 in 2022 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 2359.42% in 2024, down 435.0% in 2024.
• Over 5 years, Change in Receivables stood at -$36000.0 in 2022, then surged by 655.56% to $200000.0 in 2023, then slumped by 435.0% to -$670000.0 in 2024, then surged by 2104.78% to $13.4 million in 2025, then sank by 50.25% to $6.7 million in 2026.
• The last three Change in Receivables figures came in at $6.7 million (Q2 2026), $2.6 million (Q1 2026), and $13.4 million (Q4 2025), per Business Quant data.